Your browser doesn't support javascript.
loading
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L; Poon, Jennifer; Small, Karen A; Jou, Ying-Ming; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Statkevich, Paul; Sankhala, Kamelesh K; Sarantopoulos, John; Cleary, James M; Chirieac, Lucian R; Rodig, Scott J; Bannerji, Rajat; Shapiro, Geoffrey I.
Afiliación
  • Mita MM; Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Mita AC; Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Moseley JL; Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Poon J; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Small KA; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Jou YM; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Kirschmeier P; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Zhang D; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Zhu Y; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Statkevich P; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Sankhala KK; Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Sarantopoulos J; Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Cleary JM; Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Chirieac LR; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Rodig SJ; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Bannerji R; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
  • Shapiro GI; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
Br J Cancer ; 117(9): 1258-1268, 2017 Oct 24.
Article en En | MEDLINE | ID: mdl-28859059
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Piridinio / Quinasas Ciclina-Dependientes / Compuestos Bicíclicos Heterocíclicos con Puentes / Inhibidores de Proteínas Quinasas / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Piridinio / Quinasas Ciclina-Dependientes / Compuestos Bicíclicos Heterocíclicos con Puentes / Inhibidores de Proteínas Quinasas / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido